Janssen Says Investigational Treatment for Myeloma Gets FDA Breakthrough Designation

Date : 12/06/2019 @ 10:03PM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 150.13  0.04 (0.03%) @ 12:59AM
After Hours
Last Trade
Last $ 150.40 ▲ 0.27 (0.18%)

Janssen Says Investigational Treatment for Myeloma Gets FDA Breakthrough Designation

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

3 Months : From Nov 2019 to Feb 2020

Click Here for more Johnson and Johnson Charts.
   By Stephen Nakrosis 
 

The Janssen Pharmaceutical Cos. of Johnson & Johnson said Friday the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for JNJ-68284528, an investigational therapy to treat certain myeloma patients.

Janssen said the designation was supported by results from its Phase 1b/2 CARTITUDE-1 study, a multicenter clinical trial evaluating the safety and efficacy of JNJ-4528 currently active in the U.S.

"The primary objective of the Phase 1b portion of the study is to characterize the safety of JNJ-4528 and confirm the dose for future clinical trials," the company said.

 

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

December 06, 2019 16:48 ET (21:48 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.